Imaging Probes   I   Catalogue


≥98% (HPLC)

Retinoic Acid Analogue


≥95% (HPLC)
Retinoic Acid Analogue

Biochemical/physiological Actions

Strong ligand for retinoic acid receptor proteins


  • Fluorescence microscopy
  • Fluorescent retinoid binding assay
  • Fluorescence spectroscopy

Features and Benefits

LightOx™19 is a synthetic analogue of all-trans-retinoic acid (ATRA), that exhibits solvatochromatic fluorescence emission when excited with UV or 405 nm light. The compound is a strong ligand for the retinoic acid receptor proteins (RARs) and related cellular retinoic acid binding proteins (CRABPI/II) and can, therefore, be used as a replacement for ATRA in cellular assays involving retinoid signalling processes.

LightOx™19 can be utilised to study retinoid behaviour using fluorescence microscopy, employed in a competitive fluorometric ligand-binding assay for direct determination of the strength of binding of non-fluorescent retinoids to a protein target, and as a fluorophore in fluorescence spectroscopy.

Purchase with Merck

LightOx™19 is referred to as DC360 in the following papers

Fluorescent Retinoic Acid Analogues as Probes for Biochemical and Intracellular Characterization of Retinoid Signaling Pathways

View PDF

Genomic and non-genomic pathways are both crucial for peak induction of neurite outgrowth by retinoids

View PDF

CYP26A1 gene promoter is a useful tool for reporting RAR-mediated retinoid activity

View PDF
More Imaging Probes
All available to purchase from Merck
Imaging Probes Catalogue